(Corrects to add source)
Jan 9 (Reuters) - Blueprint Medicines Corp:
* BLUEPRINT MEDICINES - CONTINUES TO PURSUE CONDITIONAL MARKETING AUTHORIZATION FOR AVAPRITINIB FOR PDGFRA D842V MUTANT GIST IN EU
* BLUEPRINT MEDICINES - ANTICIPATES DECISION FROM EUROPEAN COMMISSION ON PDGFRA D842V GIST INDICATION IN Q3 2020 Source text: [bit.ly/306obBp] Further company coverage: (Reuters.Briefs@thomsonreuters.com)
Our Standards: The Thomson Reuters Trust Principles.